In the model of Kras-activated, Trp53-deleted (KP) lung cancer (in which a Cre-encoding adenovirus is instilled into the trachea of mice bearing a mutant Kras antigen downstream of a LOX-Stop-LOX cassette, as well as Cre-excisable Trp53)30, the combination therapy was more efficient in reducing tumor burden than either (R)-crizotinib or CDDP alone (Fig. 5a-d). This evidence concerns the gene LOX and neoplasm.